Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Plus Durvalumab in EGFR-Mutated NSCLC Transformed to SCLC/Neuroendocrine Tumors
NCT04538378Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Started Jul 2021; status: terminated.
02
Drugs
olaparibdurvalumab
03
Conditions
non-small cell lung carcinoma (NSCLC)small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04538378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538378.